Lemborexant: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Lemborexant. Educational only — not medical advice.
Labeled uses
DAYVIGO is indicated for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance [see Clinical Studies ( 14.1 )] .
Source: FDA labeling via NIH DailyMed (set 7074cb65…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.